{
    "clinical_study": {
        "@rank": "136256", 
        "arm_group": [
            {
                "arm_group_label": "prostate cancer", 
                "description": "prostate adenocarcinoma in pathologic evaluation"
            }, 
            {
                "arm_group_label": "control", 
                "description": "benign prostatic diseases in pathologic evaluation"
            }
        ], 
        "biospec_descr": {
            "textblock": "serum, prostatic tissue"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the\n      prostate cancer, its specivity is not sufficient. Several PSA variations were defined in\n      order to increase the specivity of the test, but they aren't much more effective than the\n      PSA alone for detection of disease.\n\n      In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat\n      cancer disease.\n\n      In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA),\n      zinc/PSA, levels for early detection of the prostate cancer."
        }, 
        "brief_title": "Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer Detection", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination\n\n        Exclusion Criteria:\n\n        usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy,\n        older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..),\n        PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in\n        pathologic evaluation."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "patient with LUTS(lower urinary tract symptomps) and elevated serum PSA levels/suspicious\n        rectal examination who undergone transrectal ultrasonography guided prostate biopsy"
            }
        }, 
        "enrollment": {
            "#text": "480", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013180", 
            "org_study_id": "Zinc/PSA"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Prostate cancer, PSA, zinc, zinc/PSA", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Istanbul", 
                    "country": "Turkey", 
                    "state": "Bagcilar", 
                    "zip": "34100"
                }, 
                "name": "Bagcilar Training and Research Hospital-Depertmant of Urology"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_groups": "2", 
        "official_title": "Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "assesment of efficacy of zinc/PSA on prostate cancer detection", 
            "safety_issue": "No", 
            "time_frame": "measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013180"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bagcilar Training and Research Hospital", 
            "investigator_full_name": "Mustafa Zafer Temiz", 
            "investigator_title": "resident", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Bagcilar Training and Research Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bagcilar Training and Research Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}